Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) (DMF-CTCL)
Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Sponsor: KKS Netzwerk
A PHASE2 clinical study on Cutaneous T Cell Lymphoma, this trial is completed. The trial is conducted by KKS Netzwerk and has accumulated 8 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- KKS Netzwerk
- Klinikum Krefeld
- Klinikum Ludwigshafen
- Klinikum Minden
- Universitätsklinikum Kiel
- Universitätsmedizin Mannheim
- Wuerzburg University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .